Brief: Inkmune Demonstrates Safety & Increased Nk-Cell Activity In First Dosing Cohort
26/09/2024 13:18
Sept 26 (Reuters) - INmune Bio Inc INMB.O :
* INMUNE BIO INC: INKMUNE™ DEMONSTRATES EXCELLENT SAFETY &
INCREASED NK-CELL ACTIVITY IN FIRST DOSING COHORT
Source text for Eikon: ID:nGNX8ZqNwB
Further company coverage: INMB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inmune Bio
See all newsBrief: Inmune Bio - Enters Master Services Agreement With Uniphar For Ebstrocel International Commercialization
Brief: Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027
INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary
INmune Bio Q2 net loss narrows on lower impairment charges
INmune Bio Inc expected to post a loss of 21 cents a share - Earnings Preview